# A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

> **NCT02138292** · PHASE1 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 27 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Trametinib (2mg)/Digoxin (.25mg)

## Key facts

- **NCT ID:** NCT02138292
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2017-02-23
- **Final completion:** 2017-02-23
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2018-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02138292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02138292, "A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02138292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*